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Abstract
Safety of concomitant use of veterinary products 
is of clinical interest. A series of studies was per-
formed to evaluate the chemical compatibility and 
short term dermal and systemic safety of an imi-
dacloprid/ flumethrin collar (Seresto®/ Foresto®, 
Bayer) used concomitantly with spot-on or tablet 
formulations.
Chemical compatibility was evaluated in-vitro 
(study reference A) on collar pieces, followed by two 
small, non-controlled clinical studies (study refer-
ence B) in both, cats and dogs. The studies showed, 
that certain solvents affected the collar in-vitro, but 
not in their marketed formulations.
Dermal and systemic safety of different spot-on 
or tablet formulations was first evaluated in a 
small, non-controlled clinical study (study refer-
ence C) in cats and dogs, via clinical observations 
only, followed by controlled clinical safety studies 
of concomitant use with imidacloprid/ moxidectin 
(Advocate®/ Advantage® Multi, Bayer) in dogs and 
cats (study reference D) and emodepside/ praziqu-
antel (Profender®, Bayer) in cats (study reference 
E), assessing safety aspects by clinical observations 
and statistical analyses of hematology and clinical 
chemistry parameters compared to baseline values 
and between treated and control groups.
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Dermal safety findings over all clinical studies 
(study references B to E) matched those already 
described for the respective products and included 
transient cosmetic changes (oily hair and crystal for-
mation) at the site of spot-on application and broken 
hair, transient alopecia and skin alterations at the 
site of collar application. There were no indications 
of these findings aggravating under the conditions 
of concurrent use. There were no systemic safety 
findings of clinical significance in any of the clinical 
safety studies (study reference C to E). Assessment 
of blood parameters revealed some deviations from 
baseline levels and from the reference range in dogs 
as well as in cats, but no clinical relevance could be 
deduced. Hematology and clinical chemistry results 
confirmed the safety of the concomitant treatment.
It is concluded that Seresto® is chemically com-
patible with solvents used in major spot-on for-
mulations on the market and is dermally and 
systemically safe for adult dogs and cats when 
used concomitantly with Advocate® and Profender® 
spot-on formulations.
Introduction
Externally applied antiparasitic drugs used on 
cats and dogs have “evolved” to often also focus 
on prevention of transmissible diseases, as well as 
formulations developed to control both, ecto- and 
endoparasites (Beugnet and Franc 2012). This is 
not only the case for externally applied antipar-
asiticides, but also formulations for which oral 
efficacy against these parasite types have been 
evaluated (Snyder and Wiseman 2012). However, 
there is currently no single product on the mar-
ket that can treat and prevent the entire range of 
ecto- and endoparasite taxa affecting companion 
animals. Despite attempts to broaden the spec-
trum of parasite species targeted, the use of com-
binations of antiparisitic drugs is likely to remain 
the only therapeutic and preventative solution for 
many years to come (Beugnet and Franc 2012). 
As a result, concomitant treatment with products 
targeting different parasites is a fact of life for vet-
erinarians and pet owners. The safety aspect of 
concomitant use is of interest for any newly intro-
duced formulation. This article presents a series of 
studies evaluating the chemical compatibility and 
dermal and systemic safety of a recently introduced 
ectoparasiticidal imidacloprid 10 %/flumethrin 
4.5 % collar (Seresto®/Foresto®, Bayer), when used 
concomitantly with topical and oral parasiticidal 
treatments. These are the first published studies 
which evaluate concomitant use of the Seresto® 
collar.
The Seresto® collar is designed to provide long-
term protection for up to 8 months against fleas 
and ticks. A long term efficacy and safety study 
showed that the collar reduced flea counts by at 
least 95 % and tick counts by at least 90 % for a 7 to 
8 month period in both cats and dogs. Safety was 
confirmed with mainly minor observations local-
ised to the application site (Stanneck et al. 2012a). 
The collar is licensed for the treatment and pre-
vention of flea infestations (Ctenocephalides felis), 
treatment of tick infestations (Ixodes ricinus and 
Rhipicephalus turanicus in cats, Ixodes ricinus, 
Rhipicephalus sanguineus and Dermacentor retic-
ulatus in dogs) and infestations with chewing lice 
(Trichodectes canis) (Horak et al. 2012; Stanneck 
et al. 2012b; Stanneck et al. 2012c). 
The collar also exhibits repellent (anti feeding) 
efficacy and has the potential to prevent infections 
with flea and tick transmitted agents (Fourie et al. 
2012; Fourie et al. 2013a; Fourie et al. 2013b; Lap-
pin et al. 2013; Otranto et al. 2013, Reichard et al. 
2013; Brianti et al. 2014). 
The collar contains two actives, the insecticide 
imidacloprid active against fleas and lice, and the 
acaricide flumethrin active against ticks and mites 
(Stanneck et al. 2012b; Stanneck et al. 2012c; Bri-
anti et al. 2013; Smith et al. 2013). The actives 
themselves have a relatively long history. Imida-
cloprid was registered in Europe in 1997 for use as 
a veterinary medicinal product in cats and dogs, 
while flumethrin was registered in Europe even 
earlier in 1986 for use as a veterinary medicinal 
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product for companion and food producing animals. 
Imidacloprid is a neonicotinoid insecticide which 
acts as a strong agonist at nicotinic acetylcholine 
receptors (nAChRs) on the post-synaptic mem-
brane, causing sustained depolarization of the 
neuron and death of the flea or louse (Bai et al. 
1991). Imidacloprid is highly selective for insect 
nAChRs, to which it binds up to 1,000 times more 
strongly than to mammalian nAChRs, so it exhib-
its extremely low mammalian and environmental 
toxicity (Casida et al. 1993; Methfessel 1992). In 
addition to killing adult fleas, imidacloprid also 
exhibits larvicidal efficacy which controls flea lar-
vae in the pet´s own environment. Flumethrin is a 
type II pyrethroid with excellent acaricidal effica-
cy. It kills ticks by binding to voltage gated axonic 
sodium channels in neural tissue and keeping them 
open for longer than physiologically normal. This 
results in membrane depolarization, repetitive 
discharges and synaptic disturbances, leading to 
hyperexcitatory symptoms of poisoning (Narahashi 
1996). Flumethrin has a simple metabolism and 
can be excreted directly via bile and faeces without 
the need for glucuronidation, a phase II conjuga-
tion pathway involved in metabolism and excretion 
of other pyrethroids (Kaneko 2010). Cats have only 
limited capacity for glucuronidation and thus have 
an increased sensitivity towards other pyrethroids. 
However, their sensitivity towards flumethrin is 
comparable to dogs, as shown in toxicological stud-
ies, so flumethrin can be considered to be safe for 
cats (Stanneck et al. 2012c) 
The design of the Seresto® collar is unique. Imida-
cloprid and flumethrin are blended with skin-com-
patible neutral oils in a polyvinyl chloride (PVC) 
matrix of the collar. Neutral oils are used as plas-
ticizers instead of commonly used but potentially 
harmful phthalate ester plasticizers. Stearic acid is 
used as the lubricant. The safety of the collar on the 
animal´s neck is assured by the use of these com-
pounds, as neutral oils are safe enough to be used in 
the cosmetic industry and stearic acid is so non-toxic 
that it is used as a hardener in confectionary items. 
The polymer matrix provides fast and continuous 
release of the active ingredients which are distrib-
uted over the entire body surface within hours of col-
lar application. However, there have been no studies 
published to date about the chemical compatibility 
of the collar with spot-on formulations.
This is of particular interest because spot-on formu-
lations are normally applied in the vicinity of the 
collar and so could potentially damage the collar 
structure. Twelve widely used solvents from spot-
on formulations and one solvent of possible future 
interest were selected for in vitro testing (study ref-
erence A for ease of discussion), with results con-
firmed by follow-up in-vivo chemical compatability 
tests (study reference B for ease of discussion). All 
solvents tested are listed in Table 1.
The long term nature of the collar treatment has 
the advantage that pet owners need apply the col-
lar only once to gain long term protection. How-
ever, the long term nature of the collar also means 
that the question of potential interference of con-
comitant treatment with other parasiticides may 
well arise.
The treatment scenarios considered were collar 
treated dogs or cats, which required an additional 
spot-on to treat or prevent nematode infections 
such as heartworm, hookworm, roundworm and 
whipworm. Collar treated animals might also 
require concomitant treatment to deal with other 
ectoparasites such as mites. 
Dogs fitted with collars might for example need a 
spot-on for the prevention and treatment of French 
heartworm, treatment of fox lungworm or demo-
dectic mange. Alternatively cats and dogs protected 
against fleas or being treated for one of the above 
conditions with a spot-on formulation might require 
collar treatment for additional protection against 
ticks. To test dermal and systemic safety of concomi-
tant treatment with the Seresto® collar, a smaller 
non-controlled safety study employing Seresto®/
Advocate®/Profender® (study reference C for ease of 
discussion) and three larger controlled safety stud-
ies (studies references D for the first two studies 
employing Seresto®/Advocate® and study reference 
E for the third employing Seresto®/Profender®) were 
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performed. In the smaller study (study reference C) 
the following two products for cats were selected as 
concomitant medication: an imidacloprid/moxidec-
tin spot-on (Advocate®, Bayer) and an emodepside/
praziquantel spot-on (Profender®, Bayer). Three 
products were selected for dogs: an imidacloprid/
moxidectin spot-on (Advocate®, Bayer), an imi-
dacloprid/permethrin spot-on (Advantix®, Bayer) 
as well as an emodepside/praziquantel oral tablet 
(Profender®, Bayer). In the larger controlled safety 
studies reported, the imidacloprid/moxidectin spot-
on (Advocate®) for both, cats and dogs, were selected 
for two studies (study reference D: Seresto®/Advo-
cate® studies), with Profender® spot-on (emodepside 
plus praziquantel) for cats in the third (study refer-
ence E: Seresto®/Profender® study). All of the prod-
ucts chosen in the safety studies are active against 
either nematodes or mites, and so could be options 
for use in the treatment scenarios outlined previ-
ously. For the scope and purpose of this manuscript, 
with specific reference to the three larger clinical 
studies performed, Advocate® and Profender® are 
of particular interest.
Although both the Seresto® collar and the Advo-
cate® spot-on formulation contain imidacloprid, 
this was not expected to cause any particular prob-
lems due to the very low mammalian toxicity of this 
active ingredient.
In target animal studies with the imidacloprid 
mono spot-on product Advantage®, there were no 
side effects seen in a 20 fold dermal overdose in 
dogs or a 24 fold overdose in cats, demonstrating 
imidacloprid´s wide safety margin (Mencke and 
Jeschke 2002). The other active in Advocate® is mox-
idectin, a macrocylic lactone of the milbemycin class, 
which binds to neuronal glutamate-gated chloride 
channels of nematodes and muscle membranes of 
arthropods leading to hyperpolarization, paralysis 
and death (Forrester et al. 2002). Advocate® was 
licensed in the European Union in 2003 and is a 
well-known treatment (Hellmann et al. 2003). 
Efficacy using this product has been demonstrated 
against fleas and mites (Krieger et al. 2005; Wenzel 
et al. 2008; Fourie et al. 2009; Le Sueur et al. 2011), 
as well as several helminth species (Conboy et al. 
2009; Traversa et al. 2009; Fok et al. 2010; Taweet-
havonsawat et al. 2010; Hellman et al. 2011; Tra-
versa et al. 2012; Austin et al. 2013) in animals as 
diverse as dogs, cats, ferrets and even reptiles and 
rodents (Mehlhorn et al. 2005). 
Advocate® has also been shown to prevent infec-
tion with certain parasites, such as the nematodes 
Spirocerca lupi and Dirofilaria repens (Le Sueur 
et al. 2011; Hellman et al. 2011; Genchi et al. 2013). 
Profender® spot-on contains both emodepside and 
praziquantel. Efficacy against a number of hel-
minths in cats have been demonstrated (Altreuther 
et al. 2005a; Altreuther et al 2005b; Charles 
et al. 2005; Reinemeyer et al. 2005; Schaper et al. 
2007; Traversa 2009; Wolken 2009; Wolken 2012; 
Taweethavonsawat et al. 2013), as has efficacy 
in dogs using the tablet formulation (Altreuther 
et al. 2009a; Altreuther et al. 2009b; Schimmel 
et al. 2009a; Schimmel et al. 2009b). Considering 
scope of activity (nematodes and cestodes), ease of 
administration (topical spot-on) as well as known 
contraindications for some of the other anthelmin-
tic actives in reptiles, this product also resolved 
limitations associated with previous antiparasitic 
treatments as far as effective anthelmintic treat-
ment in reptiles are concerned (Mans 2013). The 
product has also been used to effectively treat 
rodents (Schmahl et al. 2007). 
From the discussions above it is clear that con-
comitant use of the Seresto® collar with any of the 
two spot-on formulations highlighted (Advocate® 
or Profender®), will provide therapeutic and pre-
ventative efficacy against a very wide range of hel-
minths, ectoparasites and diseases transmitted by 
the latter. However, safety of concomitant treat-
ment of Seresto® with Advocate® or Profender® has 
not been tested before and will be of clinical inter-
est to practicing veterinarians.
The studies presented here were designed to 
answer three main questions. 
Firstly, is the new Seresto® collar polymer matrix 
chemically robust enough to withstand direct con-
tact with a spot-on formulation? 
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Secondly, are there any dermal safety implications 
for cats and dogs, when the collar is used concomi-
tantly with a spot-on formulation? 
Thirdly, is the particular combination of the actives 
(imidacloprid, flumethrin and moxidectin with ref-
erence to Seresto® used with Advocate® or imida-
cloprid, flumethrin, emodepside and praziquantel 
with reference to Seresto® used with Profender®) 
systemically safe for cats and dogs?
Materials and Methods
Study reference A: Chemical Compatibility: 
In-Vitro Testing of 13 Solvents
A total of 13 solvents were chosen for in-vitro test-
ing. In the first trial 9 commonly occurring solvents 
in spot-on formulations were chosen. In the second 
trial 3 more unusual solvents and 1 solvent of pos-
sible future relevance were chosen. The Seresto® 
collars were cut into pieces approximately three 
cm in length and were placed in small vials, each 
one containing a different solvent. The pieces were 
placed so that half of the collar was covered by 
solvent. The collar pieces were examined visually 
after 15 minutes and again after 24 hours. The col-
lar pieces were also examined manually for surface 
changes and texture after 24 hours. The solvents 
used in the two trials and their spot-on formula-
tions are shown in Table 1.
Study references B to E: General Notes on 
Animal Husbandry and Other Points Com-
mon to All Clinical Studies 
All clinical studies presented here were performed 
in accordance with Good Scientific Practice, with 
the exception of the Seresto®/Profender® study 
(study reference E) that was performed in accor-
dance with the principles of the Organisation for 
Economic Co-operation and Development Good 
Laboratory Practice (OECD GLP).
All animals described in these studies were part of 
a regularly maintained research colony and were 
returned either to the colony or transferred to an 
animal welfare station after study completion. 
Table 1: Solvents tested in-vitro and the spot-on formulations in which they are found 
Solvent (Common acronym) Trial number Used in 
Benzyl alcohol (BA) 1 Advantage®, Advocate®
Propylene carbonate (PC) 1 Advantage®, Advocate®
BA/PC (80:20) 1 Advantage®, Advocate®
N-Methyl-2-pyrrolidone (NMP)* 1 Advantix®, Droncit® 
Solketal (Isopropylidenglycerin) 1 Profender®
Diethylene glycol mono ethyl ether 1 Frontline®, Practic®
Isopropyl alcohol 1 Bolfo® Spray
Ethyl alcohol 1 Frontline®
Dimethylsulfoxide (DMSO)* 1 ProMeris®/ProMeris Duo®
Gamma-hexalactone* 2 ProMeris®/ProMeris Duo®
1-Methoxy-2-propyl-acetate* 2 ProMeris®/ProMeris Duo®
Dipropylene glycol mono methyl ether 2 Tiguvon® 
Tetrahydro furfuryl alcohol (THFA) 2 Possible future relevance
* The solvents in italics were subjected to additional in-vivo testing
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All animals were already acclimatised to the study 
facilities at the time of enrolment. Housing, light 
control, humidity control, and feeding were all 
in accordance with internal standard operating 
procedures based on the European Commission 
guidelines for the accommodation of animals used 
for experimental and other scientific purposes 
(June 18, 2007/526/EC), as well as applicable local 
guidelines (The South African National Standard: 
SANS 10386:2008: The care and use of animals for 
scientific purposes). Please note that the former 
guideline had been in use when the studies were 
designed, but has since been revised in 2013.
The clinical studies all shared animal health as a 
common inclusion criterion. All animals had to be 
in good health as determined by a physical exami-
nation conducted by a veterinary surgeon on either 
SD -2 (large safety study reference D Seresto®/Advo-
cate® studies performed in Europe) or SD 0 (chemi-
cal compatibility studies B, small safety studies C 
and safety study reference E Seresto®/Profender® 
study performed in South Africa).
With the exception of the imidacloprid/permethrin 
formulation (Advantix®) for dogs in the chemical 
compatibility study B, all spot-on products and 
Profender® tablets were administered at thera-
peutic doses according to animal body weights and 
in compliance with manufacturers´ instructions as 
detailed in the package inserts.
The animals were fitted with Seresto® collars 
according to their body weight. Dogs with a body 
weight ≤ 8 kg received a small collar (Seresto® collar 
for dogs ≤ 8 kg) and dogs with a body weight above 
8 kg received a large collar (Seresto® collar for 
dogs > 8 kg). All treated cats received a small collar 
(Seresto® collar for cats). Collars were fitted accord-
ing to label instructions: collars were adjusted 
around the animal’s neck in such a way that a 
space of two fingers remained between collar and 
neck. Excess collar was pulled through the collar’s 
buckle and a fixative loop and excess length was 
clipped off, leaving a 2 cm overlap behind the fixa-
tive loop.
Study reference B: Chemical Compatibility: 
In-vitro Clinical Studies 
Four solvents found in spot-on formulations were 
identified as affecting the collars: N-methyl-pyrrol-
idone (NMP), dimethylsulfoxide (DMSO), gamma-
hexalactone and 1-methoxy-2-propyl-acetate. Spot-on 
formulations containing these four solvents were 
next tested under conditions of normal collar use in 
two small scale non-controlled GSP clinical studies, 
one in cats and one in dogs. In cats the formulations 
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tested contained the active ingredients metaflumizon 
(ProMeris®) and praziquantel (Droncit®). In dogs the 
formulations tested contained metaflumizon/ami-
traz (ProMeris Duo®) and imidacloprid/permethrin 
(Advantix®). The studies were non-randomised and 
non-blinded as each study contained only 1 study 
group. On study day zero (SD 0) the animals were 
weighed and physically examined before being fitted 
with the Seresto® collar. The first spot-on formulation 
was applied directly after collar fitting. At the 2 hour 
time point the collars were temporarily removed, 
visually and manually inspected and the re-fitted. 
At the 24 hour time point the collars were removed, 
visually and manually inspected and then disposed of. 
On SD 9, the second spot-on formulation was 
applied to the animals directly after new collars 
were fitted. At the 2 hour time point the collars 
were temporarily removed, visually and manually 
inspected and then re-fitted. At the 24 hour time 
point the collars were removed, visually and manu-
ally inspected and then disposed of. 
Clinical assessments were performed pre-treat-
ment and approximately 2 and 24 hours post-
treatment. The following were assessed: attitude, 
behaviour, nutritional status, respiratory system, 
gastrointestinal system and cardiovascular sys-
tem. In addition general health observations were 
performed daily during the whole study period. The 
following were assessed: eyes, respiration, behav-
ioural attitude, locomotion/musculature, skin/hair, 
faeces and presence or absence of vomit.
Overview of the Chemical Compatibility Cat 
Study
A tabulated overview of the cat study is shown in 
Table 2. Three domestic shorthair cats of differ-
ent age and the same gender were enrolled onto 
the study. The first spot-on formulation tested 
on SD 0 was ProMeris®, containing the solvents 
DMSO, gamma hexalactone and 1-methoxy-2-pro-
pyl-acetate. The second spot-on formulation test-
ed on SD 9 was Droncit®, containing the solvent 
N-methyl-2-pyrrolidone. The spot-on formulations 
were applied on the cats´ necks at the base of the 
skull while the hair was divided with two fingers 
until the skin was visible. The formulations were 
applied at therapeutic dose and in accordance with 
the manufacturers´ instructions. 
Overview of the Chemical Compatibility Dog 
Study
A tabulated overview of the dog study is shown in 
Table 3. Three beagle dogs of different gender and 
the same age were enrolled onto the study. The 
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first spot-on formulation tested on SD 0 was ProM-
eris Duo® containing the solvents DMSO, gamma 
hexalactone and 1-methoxy-2-propyl-acetate. The 
second spot-on formulation tested on SD 9 was 
Advantix® spot on formulation, containing the sol-
vent N-Methyl-2-pyrrolidone. ProMeris Duo® was 
applied at therapeutic dose and in accordance with 
the manufacturers´ instructions. Advantix® was 
also applied at therapeutic dose, but in order to 
mimic a worst case scenario the whole volume was 
applied on one spot between the shoulder blades 
while the hair was divided between two fingers 
until the skin was visible. This is contrast to label 
instructions that the volume should be applied to 
four spots between the dorsal shoulder blades and 
the base of the tail.
Study reference C: Seresto®/Advocate®/Pro-
fender® study: Small Non-Controlled Clinical 
Safety Study
This small non-controlled clinical safety study 
was designed to give preliminary information on 
dermal and systemic safety of concomitant treat-
ment. The spot-on formulations chosen for use with 
cats were an imidacloprid/moxidectin formulation 
(Advocate®) and an emodepside/praziquantel for-
mulation (Profender®). The spot-on formulations 
chosen for use with dogs were an imidacloprid/
moxidectin formulation (Advocate®) and an imi-
dacloprid/permethrin formulation (Advantix®). In 
addition, dogs in group 2 were also given an oral 
emodepside/praziquantel tablet (Profender®) at the 
same time as the spot-on formulation Advantix® 
was administered. 
A total of 16 animals were used, 10 cats and 6 dogs. 
Additional inclusion criteria for these studies were 
as follows: (1) no treatments with any of the Inves-
tigational veterinary products (IVPs) for at least 
30 days before study start and (2) no recent treat-
ments with other drugs which could interfere with 
the evaluation of IVPs.
The studies were randomised but not controlled. 
Animals were randomised to study groups based 
on body weight on SD 0. 
The study groups comprised two groups contain-
ing three dogs each and two groups containing five 
cats each. All animals were fitted with collars on 
SD 0 and concomitant treatments were given on 
SD 4. The formulations were applied at therapeutic 
dose and in accordance with the manufacturers´ 
instructions.
Clinical assessments were performed on SDs 0, 
4, 5, 6 and 7 comprising assessments of attitude, 
behaviour, nutritional status, respiratory system, 
gastrointestinal system, cardiovascular system 
and application site. All animals were weighed 
on SD 0 and abbreviated general health observa-
tions were performed daily throughout the study, 
in which the following were assessed: eyes, respi-
ration, behavioural attitude, locomotion/ muscula-
ture, skin/hair-coat, faeces and presence or absence 
of vomit.
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≤ 4 kg
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0.8 ml for cats 







1, 2 10 5,6,7 Not applicable Not applicable Not applicable Performed
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Overview of Cat Part of the Seresto®/Advo-
cate®/Profender® Clinical Safety Study
A total of ten male cats of roughly the same age 
were included on the study and randomised into 
two groups each containing five cats. A tabulated 
overview of this study is given in Table 4.
Overview of Dog Part of the Seresto®/Advo-
cate®/Advantix®/Profender® Clinical Safety 
Study 
Six dogs (five males and 1 female) of different ages 
were enrolled onto the study. A tabulated overview 
of this study is given in Table 5.
Study reference D: Large Controlled Clinical 
Safety Studies on the concomitant use of the 
Seresto® collar and Advocate® spot-on in cats 
and dogs
Two studies were designed to investigate dermal 
and systemic safety of concomitant treatment 
with the imidacloprid/flumethrin (Seresto®) col-
lar, imidacloprid/moxidectin (Advocate®) spot-on 
formulation in dogs, and cats respectively. Safety 
was assessed by once daily clinical assessments 
for 14 days and by once weekly blood specimen 
collection (on SDs 7 and 14) for analyses. Pre-treat-
ment hematological and clinical chemistry blood 
parameters were compared with post treatment 
values as determined on SDs 7 and 14 and with 
those of the non-treated control group. 
Statistical analysis of hematological and clinical 
chemistry was performed on the treated and con-
trol group. In addition, the collars were observed 
daily by qualified personnel and weekly by the 
investigator or co-investigator to check the appear-
ance, integrity and fit of the collar. 
Additional inclusion criteria for both studies were 
as follows: (1) No treatment with and of the IVP 
for at least 30 days prior to study start; (2) Clini-
cally healthy based on the results of hematology 
and clinical chemistry analyses of blood samples 
taken on SDs -2 or 1.
Due to the large number of animals involved, it 
was not possible to include all animals at the same 
time and so the Seresto®/Advocate® studies were 
conducted in replicates.
Approximately two thirds of the animals were 
allocated to the treatment group (group 1) and 
one third of the animals were allocated to the 
negative control group (group 2). The dog study 
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1.0 ml for dogs 
> 4 – 10 kg
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2.5 ml for dogs 






1.0 ml for dogs 
> 4 – 10 kg
Performed
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> 10 – 25 kg
Administration of 




1 tablet for dogs 
> 6 – 10 kg
Not applicable
1.5 tablets for 
dogs > 10 – 15 kg
1, 2 6 5,6,7 Not applicable Not applicable Not applicable Performed
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was conducted in seven replicates using a total of 
77 Beagle dogs, 31 male and 46 female. The dogs 
were between 9 months and 3.8 years in age and 
with a body weight range of 6.1 to 13.6 kg. The 
number of dogs per study replicate ranged from 
6 to 17 animals. . The cat study was conducted in 
six replicates using a total of 74 European short-
hair cats, 37 male and 37 female. The cats were 
between 1.4 and 3.9 years of age and with body 
weights ranging from 2.6 to 6.6 kg. The number of 
cats per study replicate ranged from 8 to 16 ani-
mals. Table 6 gives an overview of study design, 
including the number of animals participating in 
the study and used for analysis. 
Administration of collar and spot-on
On SD 0, treatment group animals were fitted 
with collars and dosed with spot-on formulation 
in accordance with the manufacturers’ recom-
mended dose and label instructions. Directly after 
collar application the topical treatment with the 
spot-on formulation was performed at therapeutic 
dose in accordance with manufacturers’ instruc-
tions. For dogs, the spot-on was applied to one spot 
between the shoulder blades, for cats, the spot-on 
was applied to one spot at the base of the skull. 
Negative control group animals were not treated 
with either collars or spot-on formulations. 
Clinical observations
A complete physical examination was performed on 
all animals before treatment (SD -2). Observations 
on the systemic and local tolerance of the treat-
ments were performed on SD 0 pre-treatment, two 
and four hours after treatment and subsequently 
once daily until study end (SD 14). 
These observations included eyes, respiration, 
systemic signs of irritation or allergy, salivation, 
vomitus, diarrhea, behavioural changes, CNS sys-
tem and locomotion system. The application sites 
were particularly examined for changes of the hair 
coat and skin, and the collars were checked for 
their appearance, intactness and placement. If an 
animal lost its collar during the study and the col-
lar was still intact then it was reapplied; otherwise 
a new collar was applied.
Sampling
Blood samples for hematology and clinical chemis-
try were taken from all cats and dogs in both the 
treated and control groups. 
To determine baseline values, samples were taken 
before treatment (SD -2 in the dog study, SDs -2 or 
-1 in the cat study). After treatment, sampling was 
performed on SDs 7 and 14. The samples were col-
lected from the Vena (V.) jugularis or V. cephalica 
antebrachii, using a commercially available blood 
collection system. Tubes for hematology contained 
EDTA as anticoagulant while for clinical chemistry 
lithium heparin tubes were used. Samples for clini-
cal chemistry were centrifuged at approximately 
4°C and 4000 g for ten minutes. The supernatants 
were transferred to pre-labeled micro test tubes.
Samples for hematology were analysed with an 
ADVIA 120 Hematology System (Siemens Health-
care Diagnostics, Deerfield, IL, USA) in accordance 
with the manufacturers´ instructions. The follow-
ing parameters were determined: red and white 
blood cell count, differential cell count, reticulo-
cytes (RETIC), hemoglobin, packed cell volume 
and platelets. Clinical chemistry parameters were 
determined with an IDEXX VetTest 8008 Chemis-
try Analyser (IDEXX Laboratories, Inc., Westbrook, 
Table 6:  Study Design – Seresto®/Advocate® clinical safety 
studies
No. of animals in the 
treatment group 
(no. included in 
 statistical analysis)
51 (51) 50 (49)
No. of animals in the 
control group 
(no. included in 
 statistical analysis)
26 (21) 24 (19)
Clinical assessments
SD 0: pre-treatment, 
2h + 4h post treatment
Once daily from SD 1 to SD 14
Blood sampling SD -2(-1), 
SD 7, SD 14




ME, USA) in accordance with the manufacturers´ 
instructions. The following parameters were deter-
mined: albumin (ALB), alanine-aminotransferase 
(ALT), aspartate-aminotransferase (AST), creati-
nine (CREA), gamma-glutamyl-transferase (GGT), 
globulin (GLOB) and total protein (TP).
Statistical analysis
Descriptive statistics (number of valid cases, arith-
metic mean, median, standard deviation, quartiles, 
minimum and maximum) of all hematology and 
clinical chemistry values were performed sepa-
rately for the treatment and control group in both 
studies. Possible changes over time were evaluated 
by comparing SD 7 and SD 14 values to the base-
line values determined on SDs -2 or -1. 
For relative parameters (like  %LYMP) the median 
of change from baseline was used and for all other 
parameters (units other than  %) the median of the 
percentage change from baseline was used. A more 
than 10  % change was regarded as potentially rel-
evant. To compare the treatment versus the con-
trol group on the different assessment days, the 
non-parametric Wilcoxon-Mann-Whitney-U-Test 
(two-sided, alpha=0.05) was used. The analysis was 
performed using the software Testimate Version 
6.5 and Report version 6.6 from IDV Gauting.
It was recognised that single outlying cases might 
be obscured in a statistical approach. Therefore 
all individual values that were outside the refer-
ence range were additionally carefully checked 
manually.
Study reference E: Controlled Clinical Safety 
Study on the concomitant use of the Seresto® 
collar and Profender® spot-on in cats
This study was designed to investigate dermal and 
systemic safety of concomitant treatment with the 
imidacloprid/flumethrin (Seresto®) collar and an 
emodepside/praziquantel (Profender®) spot-on 
formulation in cats. For the Seresto®/Profender® 
study 20 cats included were ranked within sex 
in descending order of individual body weights 
(SD -3) and subsequently blocked into ten blocks 
of two cats each. Since sex distribution was not 
in multiples of two, the last block of each sex con-
tained only one cat. The female cat at the end of 
the list of females was allocated to the open slot in 
the last block of males and followed the assignment 
for that block. This block thus was a mixed gender 
block, whereas all other blocks were single gender 
blocks. Animal IDs were used to break ties. With-
in blocks, cats were randomly allocated to the two 
groups using random numbers generated in Micro-
soft Excel, and sorting these numbers in ascend-
ing order. Group 1 (untreated control) consisted 
of 6 females and 4 males and group 2 (treated) 
consisted of 7 females and 3 males. The cats were 
between 15 months and 6.2 years in age and with a 
body weight range of 3.1 to 5.2 kg. Additional inclu-
sion criteria for the study was as follows: (1) No 
treatment with and of the IVPs for at least 30 days 
prior to study start and (2) clinically healthy based 
on the results of hematology and clinical chemis-
try analyses of blood samples taken prior to treat-
ment. Table 7 gives an overview of study design, 
including the number of animals participating in 
the study and used for analysis.
Administration of collar and spot-on
On SD 0, treatment group animals were fitted with 
collars and dosed with the Profender® spot-on for-
mulation in accordance with the manufacturers´ 
recommended dose and label instructions. 
Directly after collar application, the topical 
treatment with the spot-on formulation was per-
formed at therapeutic dose in accordance with 
Table 7: Study Design – Seresto®/Advocate® studies
Variable Cat Study
No. of animals in the treatment group 
(no. included in statistical analysis)
10 (10 up to SD 
23)*
No. of animals in the control group 
(no. included in statistical analysis)
10 (10)
*  One animal in the Seresto® group was removed on SD 
24 whilst the study ended SD 28. Blood analysis, clinical 
examination and body weight results for SD 28 thus only 
available for 19 animals.
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manufacturers´ instructions. The spot-on was 
applied to one spot at the base of the skull. Nega-
tive control group animals were not treated with 
either collars or spot-on formulations. Collars were 
observed daily by qualified personnel, investigator 
or co-investigator to check the appearance, integ-
rity and fit of the collar.
Clinical observations
A complete physical examination was performed on 
all animals before treatment (SD -14 and SD -3). 
Observations on the systemic and local tolerance of 
the treatments were performed on SD 0 pre-treat-
ment, 1, 2, 3 and 4 hours after treatment and twice 
(morning and afternoon) on SD 1 and SD 2. Daily 
health observations were performed once daily 
throughout the study. Observations were similar to 
that already discussed previously for the Seresto®/
Advocate® study.
Sampling
Blood specimen samples for hematology and clini-
cal chemistry were collected from all cats in both 
the treated and control groups. To determine base-
line values, samples were taken before treatment 
(SDs -14, -3 and 0). After treatment, sampling 
was performed on SDs 3, 14 and 28. The sam-
ples were collected from the Vena (V.) jugularis 
or V. cephalica antebrachii, using a commercially 
available blood collection system. Blood speci-
mens were collected in collection tubes for clini-
cal chemistry on SDs 14, -3, 0, 3, 14 and on SD 
28. Yellow top (SST) collection tubes were used 
for serum analysis. Grey top (fluoride) collection 
tubes were used for glucose determination. The 
serum specimens were centrifuged at 3 000 rpm 
for 10  minutes and all specimens submitted to 
the laboratory test site. Parameters measured 
were total serum protein (TSP) g/L, albumin g/L, 
globulin  g/L, urea  mmol/L, creatinine  µmol/L, 
ALP (alkaline phosphatase) units/L, AST (aspar-
tate aminotransferase) units/L, ALT (alanine ami-
notransferase)  units/L, total  bilirubin  µmol/L, 
random glucose mmol/L, calcium (total) mmol/L, 
sodium  mmol/L, chloride  mmol/L, potassium 
mmol/L, phosphorus (SIP)  mmol/L, magnesium 
(mmol/L), CK  (creatinine kinase)  U/L, amyl-
ase  U/L, LDH  (lactic dehydrogenase)  U/L, 
GGT (gamma glutamyltransferase) U/L and ran-
dom cholesterol mmol/L.
EDTA (purple top) and citrate (blue top) collection 
tubes were used to collect blood specimens for hae-
matology on SDs 14, -3, 0, 3, 14 and on SD 28. The 
specimens were submitted to the laboratory test 
site. 
The parameters measured were: full blood count 
(includes red cell count, haematocrit, haemoglo-
bin, mean corpuscular volume (MCV), mean cor-
puscular haemoglobin (MCH), mean corpuscular 
haemoglobin concentration (MCHC), total white 
cell count and differential white cell count), plate-
lets, prothrombin time (PT) and activated partial 
thromboplastin time (aPTT). A blood smear was 
stained and evaluated microscopically for abnor-
mal cell morphology, and quantitative estimate of 
platelet numbers. All slides were microscopically 
reviewed. When platelet clumping was observed, 
the laboratory staff commented on the severity of 
platelet aggregation as set out below.
Platelet clumping was reported as:
1+  Scanty platelet clumping was observed   
 (very little impact) increased analyser  
value by 20
2+  Copious platelet clumping was observed  
(platelet clumping impacted actual count) 
increased analyser value by 100
3+  Proliferate platelet clumping was observed  
 (platelet count was compromised and actual 
count should read within normal to high  
limits) increased analyser value by 250
The microscopic evaluation was conducted by a per-
son familiar with the microscopic characteristics of 
normal cat blood smears.
Statistical analysis
The emphasis of the statistical analysis was on 
the change from baseline values in each of the 
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haematology and clinical chemistry parameters. 
The magnitude, and specifically the clinical rel-
evance of such changes, were evaluated and inter-
preted descriptively from a clinical point of view. 
The following outlined the statistical approach:
•	 The individual haematology and clinical chem-
istry values on all test days were tabulated 
separately for each variable and each group, 
together with the following descriptive statis-
tics: mean, standard deviation (StDev), coef-
ficient of variation (CV %), geometric mean, 
geometric StDev, median, minimum, maximum 
and the number (N) observations in that group. 
•	 The individual and mean changes and percent-
age changes from baseline (preadministration 
values on SD 3 to SD 0) and each of the post-
administration days were calculated for each of 
the two groups. The mean changes from base-
line of the groups were compared descriptively. 
•	 The number of SD 0 and post-administration 
values that fell outside the reference range 
for a specific laboratory parameter were cal-
culated and listed in tables. The reference 
range for each laboratory parameter was 
calculated as the minimum and maximum 
values at baseline (SD -3) across all groups. 
•	 The SD 0 and post-administration values were 
compared to the baseline values in a withi-
nadministration comparison by means of an 
ANOVA with an animal and observation time 
(baseline, SD 0 and post-administration) as 
effects. Since the aim of the analysis was to 
statistically evaluate the significance of chang-
es in parameters from baseline in conjunction 
with relevant clinical changes, a change from 
baseline that was statistically not significant 
(p > 0.05), did not necessarily indicate that 
the difference was not clinically relevant. 
Similarly, a statistical significant change 
from baseline was not necessarily interpreted 
as a clinically relevant finding, but was rath-
er considered a finding that necessitated a 
careful review from a clinical point of view. 
•	 A between-administration comparison (group 
2 vs group 1) with respect to the changes from 
baseline, was also performed by means of an 
ANOVA with an administration effect. The 
resulting p-values were interpreted carefully 
as outlined above.
Approach to the interpretation of statistical 
results
The strategy outlined below was followed to point 
out potential differences which would warrant fur-
ther clinical review:
1. If there were any values on SD 0 or any specific 
post-administration day in at least one animal 
in a particular test group, that were outside the 
reference range, and
2. If the difference in the mean values for that 
particular parameter between the specific test 
group and the corresponding control group was 
statistically significant from the betweengroup 
comparison, and
3. If the within-group comparison for that par-
ticular test group and parameter from baseline 
to that specific SD 0 or postadministration day 
was statistical significant, that case was high-
lighted for further review.
The reason behind condition (1) above was, that a 
change from baseline which remained within the 
reference ranges was not of concern, the reason 
behind condition (2) above was, that the difference 
in the change from baseline between a test and cor-
responding control group was of concern, but only if 
this difference was due to a significant change from 
baseline in the test group, and not in the control 




Study reference A: Chemical Compatibility: 
In-Vitro Testing of 13 Solvents
The results are shown in Table 8. The collar was 
not affected by 8 of the 13 solvents used. Four of the 
five solvents that affected the collar in-vitro were 
further subjected to in vivo testing to find out if 
they compromised collar use under normal condi-
tions. One solvent (THFA) is not currently used in 
spot-on formulations and was therefore not tested 
further.
 
Study reference B: Chemical Compatibility: 
Clinical in–vivo Study with final formulation
Chemical Compatibility of Collars
There were no changes in texture, form or consis-
tency in any of the collars in either of the stud-
ies at any of the timepoints. One collar in the cat 
study was slightly oily at the 2 hour timepoint after 
ProMeris® was applied but the oiliness had disap-
peared by the 24 hour inspection timepoint. In the 
dog study, the permanent marker was blurred at 
the 2 hour timepoint in the collar of one dog after 
ProMeris® was applied. The second collar from the 
same dog was slightly oily at the 2 hour timepoint 
after Advantix® was applied.
Clinical Observations and Results
There were no adverse events regarding general 
health in any of the animals.
Cat study: After treatment with both the meta-
flumizon (ProMeris®) and praziquantel (Droncit®) 
spot-on formulations, all cats showed slight to 
moderate oily hair coat changes at the application 
site at the 2 hour observation time point. With 
ProMeris®, a slight to moderate malodour was also 
noticed at the 2 hour observation time point, and 
in two cats the hair was still oily 24 hours after 
product application. With Droncit®, all three cats 
had very slight to slightly white crystals on the hair 
tips 24 hours after application.
Dog study: After treatment with the metaflumizon/
amitraz (Pro Meris® Duo) formulation at the 2 hour 
observation point, all three dogs showed mod-
erately oily hair with moderate malodour at the 
application site. In one dog additionally a moder-
ate amount of whitish crystals at the hair tips was 
noticed. 
At the 24 hour observation point, the hair of two 
dogs was still very slightly oily and in one dog the 
amount of crystals was unchanged, slight malodour 
was still noticed in all dogs. The ProMeris® Duo 
formulation is in the meantime not marketed any 
longer in most countries, however, as a formula-
tion using comparable excipients may be marketed 
again in the future, it was deemed still interesting 
to report the results.
After treatment with the imidacloprid/permethrin 
(Advantix®) formulation at the 2 hour observation 
point, all three dogs showed slightly oily hair and 
two dogs had a slight amount of crystals at the hair 
tips. At the 24 hour observation point, very slight 
to slightly white crystals on the hair tips and slight 
oily hair could be observed at the application site 
in two dogs.
Study reference C: Small Non-Controlled 
Clinical Safety Study
No clinically relevant adverse event related to der-
mal or systemic safety occurred and no abnormali-
ties concerning general health were noticed during 
the course of the study. Clinical observations were 
limited to changes in the hair coat and are given 
in details below. 
Clinical Observations: Cats
Small to medium sized areas of broken hairs 
under the collar were observed in four out of the 
ten cats. In one cat broken hairs underneath the 
collar were observed before concomitant treat-
ment on SD 4. During the observation period from 
SD 4 to SD 7, three more cats developed broken 
hairs under the collar that were small to medium 
in size. These changes remained unchanged dur-
ing the study and were considered to be treatment 
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related to the collar due to mechanical irritation. 
All cats displayed temporary local changes in hair 
coat at the application site 2 hours post-treatment 
with the spot-on formulations, comprising medium 
to severe oily hair/skin in all cats. A few crystals 
were observed in two cats at the application site 
on SD 5 and 6. The oiliness of the skin/hair had 
significantly reduced on SD 5 and had completely 
disappeared by SD 7. The white crystals also dis-
appeared by SD 7. These changes were considered 
to be treatment related to the spot-on formulation.
Clinical Observations: Dogs
Five of the six dogs showed local changes of oily 
hair and crystals in the hair coat at the application 
site after treatment with the spot-on formulations, 
but these changes had completely disappeared by 
SD 7. These changes were considered to be treat-
ment related to the spot-on formulation. 
Study reference D: Controlled safety  
studies – Seresto®/ Advocate®
Clinical observations
Dog study: All dogs tolerated the treatment well. 
Two out of 51 treated dogs showed transient skin 
alterations in the region of collar application, 
namely a crusty spot (approx. 1 cm diameter) on 
one day, respectively a moderate erythema of small 
(< 1 cm) to medium size (1 – 4cm) for about two days. 
Further findings in the treated group that were 
considered unlikely to be treatment related were 
conjunctivitis and a congested nasolacrimal duct in 
one dog, and a hot spot in the tail region of the same 
dog that showed erythema in the collar region. In 
the control group one dog also showed wounds and 
crusts in the neck region. No further clinical signs 
were present.
Cat study: Four cats showed slight behavioural 
changes after collar application consisting of licking 
at the collar and in one cat depression for one day. 
The local tolerance assessment showed transient 
skin alterations in the region of collar applications 
Table 8: Effects of Solvents on Collar (in-vitro results)
Solvent (Common acronym) Results after 15 minutes Results after 24 hours
Benzyl alcohol (BA) Unchanged Unchanged
Propylene carbonate (PC) Unchanged Unchanged
BA/PC (80:20) Unchanged Unchanged
N-Methyl-pyrrolidone (NMP)* Collar began to dissolve Collar completely dissolved
Solketal (Isopropylidenglycerin) Unchanged Unchanged
Diethylene glycol mono ethyl ether Unchanged Unchanged
Isopropyl alcohol Unchanged Unchanged
Ethyl alcohol Unchanged Unchanged
Dimethylsulfoxide (DMSO)* Unchanged
Collar swelled up, maceration 
occurred
Gamma-hexalactone* Surface changed (corroded) Collar began to dissolve
1-Methoxy-2-propyl-acetate* Unchanged Collar maybe swelled up
Dipropylene glycol mono methyl 
ether
Unchanged Unchanged
Tetrahydro furfuryl alcohol (THFA) ** Unchanged Collar deformed, surface changed
* These solvents were further tested in-vivo
**  THFA was not tested further as it is not present in commercially available spot-on formulations
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5 out of 50 treated cats, namely slight to moder-
ate erythema of small (< 1cm) to medium (1 – 4 cm) 
size, partially with exudation and crusts, which in 
one cat was topically treated for three days. Also in 
18 of the 50 treated cats collar wearing was visible 
in the form of broken hair and/or transient alope-
cia of varying degree. One cat of the treated group 
had to be excluded from the study on SD 7 due to a 
painful hip probably related to trauma. No clinical 
signs were present in the control group.















No. of animals out of refer-
ence range above/below






14 C +22.73 % 10 – 126 U/L 1/0 1/0





T -12.82 % 13 – 111 U/L 18/n.a. 19/n.a
C -23.81 % 11 – 117 U/L 6/n.a 8/n.a
Ten of 18 treated dogs with values above the RR were already outside the RR at baseline. The con-
trol group showed a greater change on the same day. Two of six control dogs with values above the 




7 T -16.67 % 0 – 3 U/L 0/n.a. 0/n.a.
14
T -41.67 % 0 – 3 U/L 0/n.a. 0/n.a.
C -75.00 % 0 – 5 U/L 0/n.a. 0/n.a.
Highly variable values were seen in both study groups. As none of the dogs showed values outside 




7 T +11.11 % 0.26 – 1.28 x 103 /µL 1/0 0/0
14 C -15.09 % 0.19 – 0.74 x 103 /µL 0/1 0/0
Deviations from RR were only slight in both dogs and of no clinical relevance. Both dogs showed 




7 C -12.50 % 0.01 – 0.17 x 103 /µL 5/n.a. 3/n.a.
14
T -12.50 % 0.01 – 0.19 x 103 /µL 8/n.a. 11/n.a.
C +20.00 % 0.02 – 0.20 x 103 /µL 5/n.a. 3/n.a.
Six of eight treated dogs with elevated values on SD 14 were already above the RR at baseline 




7 C -13.27 % 18.2 – 112.9 x 109/µL 0/0 1/0
14 T -14.40 % 13.3 – 162.1 x 109/µL 1/0 3/0




7 C +18.62 % 1.92 – 5.43 x 103/µL 0/1 0/1





7 C 20.00 % 0.09 – 0.81 x 103/µL 5/n.a. 4/n.a.




14 C 20.00 % 0.01 – 0.14 x 103/µL 0/n.a. 0/n.a.
Value variations observed were within RR. 
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In both studies most animals showed cosmetic 
changes at the site of spot-on application. These 
were an oily appearance and sometimes crystalli-
zation at the tip of the hairs. The changes occurred 
for a maximum of two days after spot-on treatment 
and were fully reversible.
Collar observations
The treated group of 51 dogs were fitted with col-
lars and all collars were found to fit correctly, the 
integrity of the collars remained intact and none 
of the collars had to be replaced during the study.
The treated group of 50 cats were fitted with collars 
and collar observations revealed that 33 collars 
had chewed ends and 5 collars were chewed all 
over. The integrity of the collar remained never-
theless intact.
Blood hematology and clinical chemistry
No clinically relevant changes were detected for 
any parameter in the dog or cat study.
All individual hematology and clinical chemistry 
values determined on SD 7 and SD 14 were sta-
tistically evaluated for the change from baseline 
values on SD -2. More than a 10 % change from 
baseline was regarded as potentially relevant. All 
clinical chemistry parameters and some hematol-
ogy parameters were first measured as numerical 
values which were then converted into percentages 
to allow this cut off point to be applied. Increase as 
well as decrease within the reference range (RR) 
was found in all parameters in both, treated and 
control groups on SDs 7 and 14. 
The comparison of the treatment versus the control 
group on the different assessment days with the 





No. of animals out of reference range 
(above/below)




higher values in control group
2/0 1/0




higher values in treatment group
7/1 2/2
Slight reduction as well as slight elevation was seen in both study groups, with no clear pattern that 
could be related to treatment. Six of eight treated dogs with values outside the RR on SD 7 had nor-
mal values on SD 14. One treated dog had a high value already at baseline, but constantly decreas-





higher values in treatment group
2/0 0/0
Both treated dogs had elevated values already at baseline, constantly decreasing over time. Increase 








higher values in control group
4/n.a. 5/n.a.
Four of seven treated dogs with elevated values after treatment were already outside the RR at 
baseline. Elevations in the other dogs were only slight (maximum 810/µl). In the control group values 




higher values in control group
8/n.a. 5/n.a.
Six of eight treated dogs with elevated values on SD 14 were already outside the RR at baseline. 




(two-sided, alpha=0.05) showed statistical signifi-
cant but clinically non relevant changes.
The significance of individual values can be 
obscured by statistics, so in addition to all the sta-
tistical group work every individual value for each 
dog and cat was also carefully checked and no clini-
cally relevant changes were detected.
Dog study: Of the relative parameters assessed for 
hematology, median changes from baseline were 
less than 10 % in both treated and control groups 
of dogs for hematocrit (HCT) and percentages of: 
neutrophil granulocytes, lymphocytes, monocytes, 
eosinophil granulocytes, basophil granulocytes, 
leukocytes and reticulocytes.
For clinical chemistry, the medians of the percent-
age changes from baseline were less than 10 % in 
both treated and control groups of dogs for albumin 
(ALB), creatinine (CREA), globulin (GLOB) and 
total protein (TP).
Parameters with a greater than 10 % change from 
baseline and values outside the reference range 
are shown in Table 9. As can be seen from the 
comments in the table, none of these were con-
sidered to be clinically relevant. The comparison 
of the treatment versus control group on the dif-
ferent assessment days with the non-parametric 
Wilcoxon-Mann-Whitney-U-Test results showed 
statistically significant changes for only 5 values, 
all of which were determined as being not clinically 
relevant for the reasons shown in Table 10 below.
Cat study: Of the relative parameters assessed for 
hematology, median changes from baseline were 
less than 10 % in both treated and control groups 
of cats for hematocrit (HCT) and percentages of: 
neutrophil granulocytes, lymphocytes, monocytes, 
eosinophil granulocytes, basophil granulocytes, 
leukocytes and reticulocytes. 
For clinical chemistry, the medians of the percent-
age changes from baseline were less than 10 % 
for albumin (ALB), creatinine (CREA), globulin 
(GLOB) and total protein (TP). 
Parameters with a greater than 10 % change from 
baseline and values outside the reference range are 
shown in Table 11. As can be seen from the com-
ments in the table, none of these were considered 
to be clinically relevant.
The comparison of the treatment versus control 
group on the different assessment days with the 
non-parametric Wilcoxon-Mann-Whitney-U-Test 
results showed statistically significant changes 
for only 4 values, all of which were determined as 
being not clinically relevant for the reasons shown 
in Table 12.
Study reference E: Controlled safety  
studies – Seresto®/Profender®
Clinical observations
All cats tolerated the treatment well. Three out of 
ten cats in the untreated control group (group 1) 
presented with slight scaling during all local 
tolerance observations time points. All cats in the 
Seresto®/Profender® treated group 2 presented 
with cosmetic changes (spiking and white deposits 
on hair tips) recorded on the spot-on application 
site on SD 0 to SD 2. One cat had slight scaling 
recorded on SD -3 and one cat on SD 2. One cat had 
a white deposit on her skin on the spot-on applica-
tion site recorded on SD 2. No observations were 
recorded that could be considered as a results of the 
Seresto collar. The cosmetic changes at the site of 
spot-on application were fully reversible.
With reference to daily health observations, one cat 
in the Seresto®/Profender® treated group 2 present-
ed with abnormal clinical signs where a relation 
to treatment could not be ruled out. The cat devel-
oped moist dermatitis with superficial skin lesion 
on her dorsal neck. This was observed for the first 
time during the clinical examination on SD 14 and 
a relation to treatment could not be ruled out. As 
the condition did not improve, it was decided to 
remove the collar on SD 24 until the symptoms 
had disappeared. Twenty-five days afterwards, 
the skin lesion was healed completely without any 
additional treatment. All other post-treatment 
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observations in the other animals were considered 
to be not test item related.
Collar observations
The treated group of 10 cats were fitted with col-
lars and all collars were found to fit correctly, the 
integrity of the collars remained intact and none 
of the collars had to be replaced during the study.
Blood hematology and clinical chemistry
With reference to both, clinical chemistry and hae-
matology, no clinically significant changes from 
baseline were seen during the study. One cat in 
Seresto®/Profender® treated group 2 showed slight-
ly elevated values outside the reference ranges for 
ALT and AST on SD 14 and SD 28. However, no 
other related parameters showed any abnormali-
ties and the cat was clinically healthy.














No. of animals out of reference 
range above/below






7 T -18.63 % 5.5 – 17.16 x 103 /µL 0/2
2/1
14 T -19.89 % 4.04 – 17.01 x 103 /µL 0/7
Deviations from RR were only slight and the corresponding differential cell count of no clinical rel-





T -16.98 % 2.38 – 9.35 x 103 /µL 0/5 0/2
C -12.93 % 0.23 – 14.84 x 103 /µL 1/5 0/0
14
T -26.56 % 2.19 – 8.11 x 103 /µL 0/8 0/2
C -12.85 % 2.72 – 14.85 x 103 /µL 1/1 0/0




7 T -14.01 % 1.26 – 7.59 x 103 /µL 4/3
8/2
14
T -19.13 % 1.11 – 8.16 x 103 /µL 4/6
C -14.58 % 1.74 – 12.98 x 103 /µL 5/1 4/0




7 C 21.74 % 0.1 – 24.39 x 103 /µL 4/n.a. 0/n.a.
14
T -11.11 % 0.06 – 0.48 x 103 /µL 0/n.a. 0/n.a.





T -22.64 % 0.18 – 2.56 x 103 /µL 4/4 8/5
C -31.01 % 0.0 – 1.88 x 103 /µL 1/9 2/3
14 T -22.64 % 0.06 – 2.21 x 103 /µL 1/8 8/5




7 C -37.50 % 0.0 – 0.16 x 103 /µL 4/n.a.
3/n.a.




7 C 40.91 % 11.9 – 74.1 x 109 /µL 0/2
0/5
14 C 30.42 % 9.1 – 54.4 x 109 /µL 0/2
Two control cats had values outside the RR already at baseline.
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Between group comparison, based on the change 
from baseline (SD -3) by means of an ANOVA in 
haematology values at all post-treatment days, 
indicated significant differences in MCV (SDs 
0 and 3), MCHC (SD 0), white cell count (SD 28), 
neutrophils Abs (SD 28) and eosinophils Abs (SDs 
3, 14 and 28). The between group comparison based 
on the change from baseline (SD -3) by means of 
an ANOVA in clinical chemistry values at all post-
treatment days, indicated significant differences in 
creatinine (SDs 14 and 28), amylase (SD 14) and 
glucose random blood (SDs 0 and 14).
The statistical analysis was designed to screen the 
results in order to point out differences between the 
test group (group 2) and the control group (group 1) 
that should be considered more closely from a clini-
cal and safety point of view. The following strategy 
was followed to point out these differences for fur-
ther review:
a  If there were any values on either SDs 0, 3, 
14, and 28 in at least one animal in a particu-
lar test group that were outside the reference 
range, and
b  If the difference in the mean values for a 
particular parameter between the test group 
(group 2) and the control group (group 1) was 
statistically significant from the between-
group comparison (from the ANOVA), and
c  If the within-group comparison for the particu-
lar test group from SD -3 (baseline) to the post-
administration day was statistical significant. 
The reason behind condition (a) above is, that a 
change from baseline which remains within the ref-
erence ranges should not be of concern, the reason 
behind condition (b) above is, that the difference in 
the change from baseline between the test and the 
untreated group is of concern, but only if this dif-
ference is due to a significant change from baseline 
in the test group, and not in the untreated group, 
as specified by condition (c).
Based on these conditions (bullets a, b and c above), 
a number of cases were detected to comply with all 
three of them. Table 13 summarises the haematol-
ogy and clinical chemistry parameters that showed 
a statistically significant change from baseline for 
five cats. All five cats were from group 2. Five of 
the eight end values were higher than the normal 
reference ranges and three were lower. None of 
these cats had abnormalities recorded from related 
parameters for the corresponding days and all cats 




higher values in treatment group
0/0 0/0




higher values in treatment group
8/6 2/6




higher values in control group
0/2 3/1
Increase as well as decrease within the RR was present after treatment in both study groups. Maxi-
mum values of up to 24870/µl were detected in the control group. Deviations in the treatment 









higher values in control group
0/17 0/2
27 treated cats showed a value below the RR on at least one occasion after treatment. 12 of these 
were below the RR already at baseline. Lowest detected value was 6 x 109/µl. Erythrocyte counts, 
hematocrit and hemoglobin were in the normal to upper range in all affected cats.
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were clinically healthy. None of these changes had 
any clinical significance or influence on the health 
of the cats. Body weight and food consumption as 
measured during the study could be regarded as 
normal for clinically healthy adult cats and were 
not influenced by the use of the test items.
Discussion
Chemical Compatibility
The results from the in-vitro study (study refer-
ence A) showed that only certain solvents found in 
spot-on formulations could potentially damage the 
Seresto® collar. Under real-life conditions small cut-
up sections of collar would never come into contact 
with such large amounts of solvent, but the study 
conditions were made deliberately extreme in order 
to identify potentially problematic solvents. The 
four spot-on solvents identified as potentially dam-
aging were then tested further in the chemical com-
patibility clinical studies (study references B and 
C), under real, yet stringent conditions, with the 
spot-on formulations being applied directly after 
collar fitting without any time interval between. 
No visible or palpable changes occurred, and the 
integrity of the collars was uncompromised. In the 
controlled Seresto®/Advocate® safety studies (study 
reference D Seresto®/Advocate® studies) the col-
lars of the 51 treated dogs and the 50 treated cats 
were observed daily by an animal caretaker or lab 
technician and weekly by the investigator or co-
investigator, and no chemical compatibility issues 
arose. The same results were obtained after daily 
observation of 10 treated cats in the Seresto®/Pro-
fender® safety study (study reference E Seresto®/
Profender® study).
Dermal Safety
There were no clinically significant dermal safety 
findings in the chemical compatibility clinical stud-
ies (study reference B). The slight to moderate oily 
hair, malodour and slightly white crystals, that 
were observed at the 2 and 24 hour timepoints, 
are symptomatic of spot-on formulations, were of 
no clinical significance and had no impact on the 
dermal health of the animals. 
There were no clinically significant dermal findings 
in the non-controlled safety studies (study refer-
ence C Seresto®/Advocate®/Profender® study). In 
these studies the animals were assessed for 7 days 
following collar and spot-on application and by 
day 7 the oily hair and crystals observed in most 
of the animals had disappeared. The oily hair and 
crystals were obviously transient in nature and 
corrected themselves within a few days of spot-on 
Table 13:  Summary of Parameters with a Statistically Significant Change from Baseline and Values outside the Reference 



















84 – 147 
µmol/L
142 µmol/L 169 µmol/L 27 µmol/L
28 142 µmol/L 155 µmol/L 13 µmol/L
Eosinophils 
Abs (x 109/L) 28 T
CC2 EE2 0.18 – 1.56 
x 109/L
1.41 x 109/L 1.71 x 109/L 0.3 x 109/L
DF8 811 0.87 x 109/L 0.06 x 109/L -0.81 x 109/L
MCHC (g/dL) 0 T DF8 811 32 – 34 g/dL 32 g/dL 31 g/dL -1 g/dL
MCV (fL)
0
T CD5 135 39 – 51 fL 51 fL 52 fL 1 fL
3
Neutrophils 
Abs (x 109/L) 28 T DF6 952
2.66 – 18.87 
fL
4.35 fL 2.40 fL -1.95 fL
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application. Such cosmetic changes at the spot-on 
application site are well described for this prod-
uct class and are of low clinical significance. The 
alterations are transient in nature and unavoid-
able with this kind of formulation.
In the large controlled Seresto®/Advocate® safety 
studies (study reference D Seresto®/Advocate® 
studies) only 2 out of 51 treated dogs, and also 
5 out of 50 treated cats, showed skin alterations 
in the region of the collar that could have been 
either concomitant treatment related or a result of 
mechanical irritation. In the Seresto®/Profender® 
safety study (study reference E Seresto®/Profend-
er® study) there was only one cat that presented 
with abnormal clinical signs (moist dermatitis with 
superficial skin lesion on her dorsal neck) where 
a relation to treatment could not be ruled out. 
Additionally in the large controlled Seresto®/Advo-
cate® safety studies (study reference D Seresto®/
Advocate® studies) broken hair and/or transient 
alopecia was visible in 18 cats. Experiences from 
previous studies had shown hair or skin alterations 
to occur after collar application, more frequently in 
cats than in dogs. They were also more frequently 
observed in the situation of laboratory studies with 
the necessity of single housing, indicating the pos-
sible impact of increased occupation with the collar 
in those specific housing conditions. The number 
of hair alterations at application site seen in this 
laboratory study exceeded those seen in a large 
multicentre field study conducted for the approval 
of the Seresto® collar, in which changes in the skin 
around and under the collar were observed to the 
same degree between cats wearing the product 
collar and cats wearing a placebo collar (Stanneck 
et al. 2012). The study was negatively controlled, 
so changes around the collar area did not arise in 
the control group, but the uneven distribution of 
affected cats over study replicates made it clear 
that in cases where alterations occurred some level 
of manipulation of the collar by the affected cats 
was involved. Many of the collar ends were chewed 
and some cats lost their collars, while only in five 
cats with skin/hair alterations the collars appeared 
untouched. We assume, that the local reactions to 
the collar strongly depend on the individual charac-
ter of the cat and the social interaction and playing 
behaviour expressed under the respective housing 
conditions. Intense interaction with tearing and 
yanking of the collar obviously increases the risk of 
hair coat and skin changes. Although the cat study 
presented here was rather short, improvement was 
already seen in some animals towards study end, 
in all but one case without additional treatment 
or collar removal. Dermal safety findings over all 
clinical studies (study references B to E) matched 
those already described for the respective products, 
there were no indications of these findings aggra-
vating under the conditions of concurrent use.
Systemic Safety
The behavioural changes seen in cats at the begin-
ning of the study reference D Seresto®/Advocate® 
studies (licking at the collar and transient depres-
sion in one cat) are of low clinical significance. Sim-
ilar observations have been made in previous trials 
and reflect the response of this mentally sensitive 
species to an unknown and new situation. 
There were no systemic safety findings of clinical 
significance in either the non-controlled (study refer-
ence C Seresto®/Advocate®/Profender® study) or the 
controlled safety studies (study reference D Seresto®/
Advocate® studies). In the controlled safety Seres-
to®/Advocate® studies (study reference D Seresto®/
Advocate® studies) both formulations contained imi-
dacloprid as an active ingredient, however it was 
not expected that the simultaneous treatment would 
lead to accumulative problems and no systemic clin-
ical effects were seen in the studies presented here. 
The high dermal safety of imidacloprid and the fact 
that the active is released steadily in low amounts 
from the collar without peak concentrations makes 
it very unlikely that a buildup of drug would occur 
with concomitant treatment. In the controlled safety 
Seresto®/Profender® study (study reference E) the 
formulations contained different active ingredients 
with no known contra-indications. As a result no 
adverse effects were anticipated.
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The assessment of a range of blood parameters 
revealed some alterations during the study course, 
in dogs as well as in cats. Deviations from baseline 
levels and from the reference range were present, 
some with statistical significant difference in the 
group comparison, but no clinical relevance could 
be deduced from these results. Hematology and 
clinical chemistry results of the current study con-
firmed the safety of the concomitant treatment.
Conclusions
The answers to the three questions posed are as 
follows. Firstly, the imidacloprid/flumethrin Seres-
to® collar is chemically robust enough to withstand 
direct contact with any spot-on formulation con-
taining any of the solvents tested. Secondly, there 
are no dermal safety implications for adult cats and 
dogs when the collar is used concomitantly with 
the spot-on formulations tested, with specific refer-
ence to Advocate® and Profender®. Thirdly, there 
are neither dermal nor systemic safety issues with 
the particular combination of the three actives imi-
dacloprid, flumethrin and moxidectin in adult cats 
and dogs, or imidacloprid, flumethrin, emodepside 
and praziquantel in adult cats. The Seresto® col-
lar is safe to use concomitantly with Advocate® 
and Profender® spot-on formulations, when used 
according to labeling instructions.
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